Comparable stake leader
Janus Henderson Group Ltd.
SEC ownership of Protara Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001359931.
Disclosed value leader
Janus Henderson Group Ltd.
Comparable rows
50/50
Latest evidence
01 Jul 2026
- Public ticker
- TARA on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Janus Henderson Group Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Janus Henderson Group Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
01 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001359931
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Protara Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Janus Henderson Group Ltd.
Comparable rows
50/50
Latest evidence
01 Jul 2026
13D/G
13F
3/4/5
Lead comparable stake: 8.4%
13D/G row: Janus Henderson Group Ltd.
Showing 1-8 of 50 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 8.4%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
8.4%
BlackRock, Inc.
6.3%
MILLENNIUM MANAGEMENT LLC
5.7%
RA CAPITAL MANAGEMENT, L.P.
4.9%
Opaleye Management Inc.
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13D/G
|
8.4%
|
$17,941,428
4,696,709 shares
|
-$1,949,354 | 30 Jun 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
6.3%
|
$17,648,661
3,387,459 shares
|
+$5,098,459 | 31 Mar 2026 |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
Company
|
5.7%
|
$12,221,470
3,201,936 shares
|
+$1,689,761 | 01 Jul 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
4.9%
|
$5,974,448
1,971,765 shares
|
-$4,423,642 | 30 Jun 2025 |
| Opaleye Management Inc. |
13D/G
3/4/5
10%+ Owner
|
4.7%
|
$7,473,600
1,730,000 shares
|
-$410,400 | 31 Mar 2025 |
| CITADEL ADVISORS LLC |
13D/G
13F
Kenneth Griffin · Company
|
4.7%
|
$7,031,811
1,627,734 shares
|
$0 | 31 Dec 2024 |
| Woodline Partners LP |
13D/G
|
3.9%
|
$5,751,035
1,331,258 shares
|
$0 | 31 Dec 2024 |
| Jupiter Topco LLC |
13F
Company
|
8.4%
|
$17,917,945
4,696,709 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$1,007,149.
Buys
$0
Insiders: 0
Sells
$1,007,149
Insiders: 2
Net
-$1,007,149
Shares: -239,419
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 239,419
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 215,687 | $0 | $882,160 | -$882,160 |
| 3-6 | 0 | 23,732 | $0 | $124,989 | -$124,989 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to Protara Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Jesse Shefferman
Net 12M change
-$1,007,149
Latest report
29 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jesse Shefferman | CEO and President, Director | $5,167,444 | -$882,160 | -15% | Mixed | 29 Jun 2026 |
| Opaleye Management Inc. | 10%+ Owner | $3,399,232 | Filing P/S | 11 Sep 2024 | ||
| Jacqueline Zummo | Chief R&D Officer | $512,065 | -$124,989 | -20% | Filing P/S | 08 Apr 2026 |
| Patrick Fabbio | Chief Financial Officer | $427,647 | Mixed | 26 Jan 2026 | ||
| Leonardo Viana Nicacio | Chief Medical Officer | $416,704 | Mixed | 16 Jan 2026 | ||
| William Conkling | Chief Commercial Officer | $364,658 | Mixed | 02 Jun 2026 | ||
| Hannah Fry | VP, Controller | $284,962 | Mixed | 26 Jan 2026 | ||
| Richard S. Levy | Director | $162,690 | Filing P/S | 15 Jun 2026 | ||
| Jathin Bandari | Chief Medical Officer | $108,305 | Mixed | 19 Jan 2024 | ||
| Blaine Davis | Chief Financial Officer | $39,464 | Mixed | 15 Jul 2022 | ||
| Martin Sebastian Olivo | Chief Medical Officer | $27,397 | Mixed | 10 Jun 2021 | ||
| Jane Huang | Director | Mixed | 15 Jun 2026 | |||
| Roger Garceau | Director | Mixed | 15 Jun 2026 | |||
| Barry P. Flannelly | Director | Mixed | 15 Jun 2026 | |||
| Michael Edward Solomon | Director | Mixed | 15 Jun 2026 | |||
| Gregory Sargen | Director | Mixed | 15 Jun 2026 | |||
| Luke M. Beshar | Director | Mixed | 15 Jun 2026 | |||
| Cynthia Smith | Director | Mixed | 15 Jun 2026 |
Recent insider transactions for Protara Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jesse Shefferman | TARA | Common Stock | Gift | -4.16% | -30,000 | 691,832 | 30 Jun 2026 | Direct | ||
| Jesse Shefferman | TARA | Common Stock | Sale | -23% | $882,160 | $4.09 | -215,687 | 721,832 | 29 Jun 2026 | Direct |
| Jesse Shefferman | TARA | Common Stock | Options Exercise | 29.9% | 215,687 | 937,519 | 29 Jun 2026 | Direct | ||
| Jesse Shefferman | TARA | Stock Option (Right to Buy) | Options Exercise | -60.4% | -215,687 | 141,313 | 29 Jun 2026 | Direct | ||
| Richard S. Levy | TARA | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 15 Jun 2026 | Direct | |||
| Michael Edward Solomon | TARA | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 15 Jun 2026 | Direct | |||
| Cynthia Smith | TARA | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 15 Jun 2026 | Direct | |||
| Gregory Sargen | TARA | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 15 Jun 2026 | Direct | |||
| Jane Huang | TARA | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 15 Jun 2026 | Direct | |||
| Roger Garceau | TARA | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 15 Jun 2026 | Direct | |||
| Barry P. Flannelly | TARA | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 15 Jun 2026 | Direct | |||
| Luke M. Beshar | TARA | Stock Option (Right to Buy) | Award | 31,000 | 31,000 | 15 Jun 2026 | Direct | |||
| William Conkling | TARA | Common Stock | Tax liability | -7.91% | -6,008 | 69,992 | 02 Jun 2026 | Direct | ||
| Jacqueline Zummo | TARA | Common Stock | Sale | -1.18% | $6,124 | $5.40 | -1,134 | 94,827 | 08 Apr 2026 | Direct |
| Jacqueline Zummo | TARA | Common Stock | Sale | -19.1% | $118,865 | $5.26 | -22,598 | 95,961 | 01 Apr 2026 | Direct |
| Jesse Shefferman | TARA | Common Stock | Tax liability | -0.85% | -8,732 | 1,021,832 | 26 Jan 2026 | Direct | ||
| Jacqueline Zummo | TARA | Common Stock | Tax liability | -3.05% | -3,724 | 118,559 | 26 Jan 2026 | Direct | ||
| Hannah Fry | TARA | Common Stock | Tax liability | -3.3% | -1,457 | 42,723 | 26 Jan 2026 | Direct | ||
| Patrick Fabbio | TARA | Common Stock | Tax liability | -4.84% | -3,261 | 64,115 | 26 Jan 2026 | Direct | ||
| Jesse Shefferman | TARA | Common Stock | Tax liability | -1.56% | -16,322 | 1,030,564 | 20 Jan 2026 | Direct | ||
| Patrick Fabbio | TARA | Common Stock | Tax liability | -4.35% | -3,063 | 67,376 | 20 Jan 2026 | Direct | ||
| Jacqueline Zummo | TARA | Common Stock | Tax liability | -5.1% | -6,578 | 122,283 | 20 Jan 2026 | Direct | ||
| Hannah Fry | TARA | Common Stock | Tax liability | -4.6% | -2,132 | 44,180 | 20 Jan 2026 | Direct | ||
| William Conkling | TARA | Common Stock | Award | 52% | 26,000 | 76,000 | 16 Jan 2026 | Direct | ||
| William Conkling | TARA | Stock Option (Right to Buy) | Award | 158,000 | 158,000 | 16 Jan 2026 | Direct | |||
| Patrick Fabbio | TARA | Common Stock | Award | 66% | 28,000 | 70,439 | 16 Jan 2026 | Direct | ||
| Patrick Fabbio | TARA | Stock Option (Right to Buy) | Award | 175,000 | 175,000 | 16 Jan 2026 | Direct | |||
| Hannah Fry | TARA | Common Stock | Award | 25.8% | 9,500 | 46,312 | 16 Jan 2026 | Direct | ||
| Hannah Fry | TARA | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 16 Jan 2026 | Direct | |||
| Leonardo Viana Nicacio | TARA | Common Stock | Award | 49.8% | 26,000 | 78,181 | 16 Jan 2026 | Direct | ||
| Leonardo Viana Nicacio | TARA | Stock Option (Right to Buy) | Award | 158,000 | 158,000 | 16 Jan 2026 | Direct | |||
| Jesse Shefferman | TARA | Common Stock | Award | 9.06% | 87,000 | 1,046,886 | 16 Jan 2026 | Direct | ||
| Jesse Shefferman | TARA | Stock Option (Right to Buy) | Award | 524,000 | 524,000 | 16 Jan 2026 | Direct | |||
| Jacqueline Zummo | TARA | Common Stock | Award | 30.4% | 30,000 | 128,861 | 16 Jan 2026 | Direct | ||
| Jacqueline Zummo | TARA | Stock Option (Right to Buy) | Award | 180,000 | 180,000 | 16 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.